{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:42:07Z","timestamp":1784619727342,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>We recently demonstrated that the histone deacetylase inhibitor valproic acid (VPA) reprograms the cisplatin-induced metabolome of triple-negative breast cancer (TNBC) cells, including a shift in hexose levels. Accordingly, here, we tested the hypothesis that VPA alters glucose metabolism in correlation with cisplatin sensitivity. Two TNBC cell lines, MDA-MB-231 (a cisplatin-resistant line) and MDA-MB-436 (a cisplatin-sensitive line), were analyzed. The glycolysis and oxidative metabolism were measured using the Glycolysis Stress Test kit. The expression of aldehyde dehydrogenases (ALDHs), enzymes linked to drug resistance, was investigated by Western blot and real-time PCR analyses. We additionally studied the influence of ALDH inhibition by disulfiram on the viability of MDA-MB-231 cells and on a TNBC patient-derived organoid system. Cisplatin treatment reduced the extracellular acidification rate in MDA-MB-436 cells but not MDA-MB-231 cells, whereas VPA addition increased the extracellular acidification rate in both cell lines. VPA further reduced the oxygen consumption rate of cisplatin-treated MDA-MB-436 cells, which correlated with cell cycle alterations. However, in MDA-MB-231 cells, the cell cycle distribution did not change between cisplatin\/VPA\u2013cisplatin treatments. In both cell lines, VPA increased the expression of ALDH isoform and ALDH1A1 expression. However, only in MDA-MB-231 cells, VPA synergized with cisplatin to augment this effect. Disulfiram sensitized the cells to the cytotoxic effects of the VPA\u2013cisplatin combination. Furthermore, the disulfiram\u2013VPA\u2013chemotherapy combination was most effective in TNBC organoids. Our results show that ALDH overexpression may act as one mechanism of cellular resistance to VPA in TNBC and that its inhibition may enhance the therapeutic efficacy of VPA\u2013chemotherapeutic drug combinations.<\/jats:p>","DOI":"10.3389\/fcell.2023.1217149","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T22:43:48Z","timestamp":1698360228000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells"],"prefix":"10.3389","volume":"11","author":[{"given":"Avital","family":"Granit Mizrahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahinoam","family":"Gugenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roa\u2019a","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nino","family":"Tetro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofra","family":"Maimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Khutsurauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hovav","family":"Nechushtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Nisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Widad","family":"Samman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Birimberg-Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Peretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/his.14129","article-title":"The prognostic significance of ALDH1A1 expression in early invasive breast cancer","volume":"77","author":"Althobiti","year":"2020","journal-title":"Histopathology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","article-title":"Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial","volume":"97","author":"Atmaca","year":"2007","journal-title":"Br. J. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/antiox12051100","article-title":"Effects of deacetylase inhibition on the activation of the antioxidant response and aerobic metabolism in cellular models of Fanconi anemia","volume":"12","author":"Bertola","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00280-015-2695-x","article-title":"Phase I trial of valproic acid and lenalidomide in patients with advanced cancer","volume":"75","author":"Bilen","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/ijms18102039","article-title":"Differential functional roles of ALDH1A1 and ALDH1A3 in mediating metastatic behavior and therapy resistance of human breast cancer cells","volume":"18","author":"Croker","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"28329","DOI":"10.18632\/oncotarget.8631","article-title":"Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism","volume":"7","author":"Debeb","year":"2016","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1002\/stem.1219","article-title":"Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT\/\u03b2-catenin signaling","volume":"30","author":"Debeb","year":"2012","journal-title":"Stem Cells"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer-the road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3892\/or.2014.3661","article-title":"Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin","volume":"33","author":"Dominguez-Gomez","year":"2015","journal-title":"Oncol. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2018.04.029","article-title":"Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer","volume":"282","author":"Dunne","year":"2018","journal-title":"J. Control Release"},{"key":"B11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Ginestier","year":"2007","journal-title":"Cell Stem Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1014798","DOI":"10.3389\/fcell.2022.1014798","article-title":"Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin","volume":"10","author":"Granit","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3892\/ijo.2014.2801","article-title":"Involvement of aldehyde dehydrogenase 1A2 in the regulation of cancer stem cell properties in neuroblastoma","volume":"46","author":"Hartomo","year":"2015","journal-title":"Int. J. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1124\/pr.111.005538","article-title":"Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application","volume":"64","author":"Koppaka","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40170-017-0168-x","article-title":"Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities","volume":"5","author":"Lanning","year":"2017","journal-title":"Cancer Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/jnci\/djn148","article-title":"Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?","volume":"100","author":"Lawenda","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"B17","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","article-title":"MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation","volume":"26","author":"Lee","year":"2017","journal-title":"Cell Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1158\/0008-5472.CAN-21-1337","article-title":"ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/s0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","article-title":"A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study","volume":"14","author":"Luu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1158\/1078-0432.CCR-07-0074","article-title":"Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond","volume":"13","author":"Mankoff","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41523-020-00197-2","article-title":"Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies","volume":"6","author":"Marra","year":"2020","journal-title":"npj Breast Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e81162","DOI":"10.1371\/journal.pone.0081162","article-title":"Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions","volume":"8","author":"Marullo","year":"2013","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1349-7006.2009.01151.x","article-title":"Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression","volume":"100","author":"Morimoto","year":"2009","journal-title":"Cancer Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1634\/theoncologist.2014-0424","article-title":"A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer","volume":"20","author":"Nechushtan","year":"2015","journal-title":"Oncologist"},{"key":"B26","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11626-021-00563-9","article-title":"Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform","volume":"57","author":"Pan","year":"2021","journal-title":"Vitro Cell Dev. Biol. Anim."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/j.drudis.2014.09.009","article-title":"Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development?","volume":"19","author":"Pors","year":"2014","journal-title":"Drug Discov. Today"},{"key":"B28","doi-asserted-by":"publisher","first-page":"47691","DOI":"10.18632\/oncotarget.17868","article-title":"Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer","volume":"8","author":"Qian","year":"2017","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e10608","DOI":"10.1016\/j.heliyon.2022.e10608","article-title":"Cisplatin for cancer therapy and overcoming chemoresistance","volume":"8","author":"Ranasinghe","year":"2022","journal-title":"Heliyon"},{"key":"B30","doi-asserted-by":"publisher","first-page":"E5429","DOI":"10.1073\/pnas.1421438111","article-title":"Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells","volume":"111","author":"Samanta","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2012.11.010","article-title":"Aldehyde dehydrogenases in cellular responses to oxidative\/electrophilic stress","volume":"56","author":"Singh","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"109940","DOI":"10.1016\/j.biopha.2020.109940","article-title":"ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with beta-catenin","volume":"125","author":"Wang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.3390\/cancers13143409","article-title":"Valproic acid and breast cancer: state of the art in 2021","volume":"13","author":"Wawruszak","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0143013","DOI":"10.1371\/journal.pone.0143013","article-title":"Assessment of interactions between cisplatin and two histone deacetylase inhibitors in MCF7, T47D and MDA-MB-231 human breast cancer cell lines - an isobolographic analysis","volume":"10","author":"Wawruszak","year":"2015","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","article-title":"Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor","volume":"31","author":"Yardley","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-16-0854","article-title":"BET inhibitors suppress ALDH activity by targeting ALDH1A1 super-enhancer in ovarian cancer","volume":"76","author":"Yokoyama","year":"2016","journal-title":"Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1038\/s41598-018-22640-y","article-title":"Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism","volume":"8","author":"Yu","year":"2018","journal-title":"Sci. Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"918778","DOI":"10.3389\/fonc.2022.918778","article-title":"ALDH1A1 in cancers: bidirectional function, drug resistance, and regulatory mechanism","volume":"12","author":"Yue","year":"2022","journal-title":"Front. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1541-7786.MCR-18-0042","article-title":"Targeting USP22 suppresses tumorigenicity and enhances cisplatin sensitivity through ALDH1A3 downregulation in cancer-initiating cells from lung adenocarcinoma","volume":"16","author":"Yun","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"795762","DOI":"10.3389\/fmed.2022.795762","article-title":"Emerging roles of aldehyde dehydrogenase isoforms in anti-cancer therapy resistance","volume":"9","author":"Zanoni","year":"2022","journal-title":"Front. Med. (Lausanne)"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1217149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T22:44:00Z","timestamp":1698360240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2023.1217149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":42,"alternative-id":["10.3389\/fcell.2023.1217149"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2023.1217149","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"article-number":"1217149"}}